AI may cut drug development time, says Biocon's Kiran Mazumdar-Shaw
Artificial Intelligence (AI) has the potential to drastically cut the time required to take a drug molecule from the lab to patients, compressing the current five-to-seven-year timeline into just one or two years, Kiran Mazumdar-Shaw of Biocon said on Tuesday. Speaking on the role of AI in life sciences, Shaw, the Executive Chairperson, Biocon Ltd, noted that accelerating this journey from lab to clinic will unlock major opportunities in precision and personalised medicine. "Ultimately the process of drug development doesn't end in the labs. It has to be validated in clinical trials. How do you pick the right patients? How do you conduct these trials in a way that gives you early readouts? "This is all what AI is going to be used for in the future. So today it takes you almost five to seven years to get a molecule from lab all the way to the patients. Can we compress that into a year or two? That is going to be the most fascinating outcome and impact," she said on the first day of t
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)